Free tool
FAERS Monitor: Vyalev
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216962 or its brand name (Vyalev, Foscarbidopa, Foslevodopa). Reports on generic versions are filed under their own applications.
Reports
8,815
Serious
7,502
85% of reports
Hospitalization
4,804
Death reported
1,446
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- on and off phenomenon1,211
- fall1,137
- hallucination892
- death758
- dyskinesia731
- tremor513
- device issue488
- general physical health deterioration465
- mobility decreased461
- infusion site erythema430
- malaise412
- asthenia397
- confusional state395
- urinary tract infection378
- gait disturbance367
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2023 | 1 |
| 2024 | 380 |
| 2025 | 4,254 |
| 2026 | 4,179 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,344 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| on and off phenomenonSignal | 1,211 | 665.3 | 626.4 | 627,813 |
| infusion site erythemaSignal | 430 | 128.2 | 116.6 | 51,396 |
| dyskinesiaSignal | 731 | 43.7 | 40.7 | 29,956 |
| hallucinationSignal | 892 | 28.6 | 26.8 | 23,505 |
| mobility decreasedSignal | 461 | 15.4 | 14.1 | 6,176 |
| device issueSignal | 488 | 13.0 | 12.0 | 5,411 |
| general physical health deteriorationSignal | 465 | 9.6 | 8.8 | 3,590 |
| fallSignal | 1,137 | 8.2 | 7.7 | 7,244 |
| tremorSignal | 513 | 7.4 | 6.8 | 2,844 |
| confusional stateSignal | 395 | 5.8 | 5.3 | 1,590 |
| urinary tract infectionSignal | 378 | 5.3 | 4.8 | 1,321 |
| gait disturbanceSignal | 367 | 4.6 | 4.1 | 1,032 |
| astheniaSignal | 397 | 2.5 | 2.3 | 369 |
| malaiseSignal | 412 | 2.2 | 2.0 | 288 |
| deathSignal | 758 | 2.1 | 2.0 | 454 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.